A new kit for radioimmunoassay of serum phospholipase A2(PLA2) with monoclonal antibody (S-0932, Shionogi, Osaka, Japan) was used to examine PLA2levels in patients with various diseases. Patients with acute pancreatitis showed significantly increased serum PLA2levels. In patients with chronic pancreatitis, significant correlations were observed between the levels of factors evaluated by the secretin test and serum PLA2levels. In patients with pancreatic cancer, serum PLA2levels varied with disease severity. Serum PLA2concentrations were within the normal range in patients with other malignant tumors, diabetes mellitus, and chronic liver diseases but were increased in patients with chronic renal failure. S-Sepharose column analysis of sera showed a small peak of pro-PLA2and a large peak of PLA2in sera from patients with severe acute pancreatitis, but a large peak of pro-PLA2in healthy controls and patients with other diseases. On G-100 gel filtration, high-molecular-weight PLA2immunoreactivity was detected in sera of patients with chronic renal failure, whereas a single peak of PLA2immunoreactivity coinciding with that of standard PLA2was detected in sera of patients with acute pancreatitis. These results suggest that (a) measurement of serum PLA2is clinically useful for diagnosis and monitoring of pancreatitis, (b) active PLA2in the circulation is dominant in severe acute pancreatitis, and (c) the kidney may be the main site of PLA2degradation or excretion.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism